Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

The habit of Googling for an online diagnosis before visiting a GP can provide early warning of an infectious disease epidemic.

18 Jan 2014

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Research findings could help decrease risk of dengue

A study by an international team of researchers led by Anna M. Stewart Ibarra, Ph.D., of the Center for Global Health and Translational Science at SUNY Upstate Medical University, has provided public health officials with information that will help decrease the risk of dengue, a life-threatening mosquito-borne viral disease that is now one of the fastest spreading tropical diseases globally.

14 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Research on flaviviruses could help in developing effective therapies for persistent infections

We generally do not devote much time to worrying about the problems faced by viruses, although understanding them may provide clues on how to combat diseases.

9 Oct 2013

Genetically modified bacterial treatment approach reduces or eliminates sleeping sickness

A tag team of two bacteria, one of them genetically modified, has a good chance to reduce or even eliminate the deadly disease African trypanosomiasis, or sleeping sickness, researchers at Oregon State University conclude in a recent mathematical modeling study.

4 Oct 2013

Researchers uncover how SARS coronavirus uses host cell to reproduce itself

UC Irvine infectious disease researchers have uncovered components of the SARS coronavirus - which triggered a major outbreak of severe acute respiratory syndrome in 2002-03 - that allow it to take over host cells in order to replicate.

23 Aug 2013

A*STAR's SIgN discovers new strategy to develop universal dengue vaccine

A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network. This breakthrough strategy opens a door of hope to what may become the world's first universal dengue vaccine candidate that can give full protection from all four serotypes of the dreadful virus.

14 Aug 2013

SIgN discovers strategy that cripples ability of dengue virus to escape host immune system

A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network (SIgN). This breakthrough strategy opens a door of hope to what may become the world's first universal dengue vaccine candidate that can give full protection from all four serotypes of the dreadful virus.

14 Aug 2013

New research may influence development of anti-viral therapies to fight against Dengue

New research into the fight against Dengue, an insect-borne tropical disease that infects up to 390 million people worldwide annually, may influence the development of anti-viral therapies that are effective against all four types of the virus.

3 Aug 2013

UC Riverside researchers develop easy-to-wear patch that makes humans invisible to mosquitoes

Technology that hampers mosquitoes' host-seeking behavior, identified at the University of California, Riverside in 2011, has led to the development of the world's first product that blocks mosquitoes' ability to efficiently detect carbon dioxide, their primary method of tracking human blood meals.

17 Jul 2013

Novel therapeutic approach prevents dengue virus replication by artificial microRNAs

Mosquito-borne dengue viruses cause an estimated 50 million cases of human dengue fever a year and are a significant public health threat worldwide. A novel therapeutic approach prevents dengue virus from reproducing in humans by targeting and silencing key regions of the dengue genome essential for viral replication.

12 Jul 2013

Discovery of new receptor could turn the tide against mosquitoes' growing advantage

In the global war against disease-carrying mosquitoes, scientists have long believed that a single molecular door was the key target for insecticide. This door, however, is closing, giving mosquitoes the upper hand.

9 Jul 2013

Researchers study existence of cross-protection between multiple strains of infectious disease

Using a unique data set spanning 40 years of dengue fever incidence in Thailand, an international team led by biostatistician Nicholas Reich at the University of Massachusetts Amherst has for the first time estimated from data that after an initial dengue infection, a person is protected from infection with other strains for between one and three years.

3 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

Ecology, evolution of infectious diseases to be highlighted at ESA's annual meeting

West Nile virus, Lyme disease and hantavirus. All are infectious diseases spreading in animals and in people. Is human interaction with the environment somehow responsible for the increase in these diseases? The ecology and evolution of infectious diseases will be highlighted at two symposia at the Ecological Society of America's annual meeting, held from Aug. 5-9 in Minneapolis, Minn.

29 Jun 2013

Dengue Fever News and Research

Further Reading